<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="777">
  <stage>Registered</stage>
  <submitdate>21/09/2005</submitdate>
  <approvaldate>4/10/2005</approvaldate>
  <actrnumber>ACTRN12605000588695</actrnumber>
  <trial_identification>
    <studytitle>Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: Evaluation of biological, clinical and imaging markers of tumour response.</studytitle>
    <scientifictitle>Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: Evaluation of biological, clinical and imaging markers of tumour response</scientifictitle>
    <utrn />
    <trialacronym>SETUP</trialacronym>
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment A=
FEC100


Epirubicin	iv over 15-30 minutes	100 mg/m2	once	every 21 days, 	4 cyles
plus
Fluorouracil	iv bolus	500mg/m2	once	every 21 days for	4 cycles
plus
Cyclophosphamide	iv over 60 minutes	500mg/m2	once	every 21 days	for 4 cycles
Treatment B
Docetaxel
	iv over 60 minutes	100 mg/m2	once	every 21 days for	4 cycles
Trastuzumab 	Iv over 15-30 min	8 mg/m2 as loading dose, subsequent dose 6mg/m2	once evewry 21 days (after completion of anthracycline)
(after completion of anthracycline)		
Subjects will receive treatment A followed by Treatment B with no wash out period
Subjects will only recieve the Trastuzumab if they are HER2 positive</interventions>
    <comparator>both arms are considered standard of care</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Identification of markers that correlate with tumour response to chemotherapy</outcome>
      <timepoint>Measured after surgical removal of tumour</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease free and overall survival.</outcome>
      <timepoint>as event occurs</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>locally advanced breast cancer</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>metastatic disease (Stage 4)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>coin toss with no restriction</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>8/04/2005</anticipatedstartdate>
    <actualstartdate>1/06/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Monash Health</primarysponsorname>
    <primarysponsoraddress>246 Clayton rd, Clayton VIC 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Monash Health</fundingname>
      <fundingaddress>Monash Cancer Centre
865 Centre rd
East Bentleigh VIC 3165</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Sanofi-Aventis</sponsorname>
      <sponsoraddress>12-24 Talavera Road
Macquarie Park NSW 2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is evaluating the effect of neoadjuvant chemotherapy with docetaxel and anthracycline in patients with advanced breast cancer. Who is it for? You may be eligible to join this study if you are a female aged 18 years or above who has a diagnosis of locally advanced breast cancer. Study details Participants in this study will be randomly (by chance) allocated to one of two groups. Participants in one group will undergo 4 cycles of chemotherapy with docetaxel followed by 4 cycles of chemotherapy with anthracycline. Participants in the other group will receive the same treatments in reverse order. The overall duration of treatment in each group is 24 weeks. All participants will be monitored for up to 5 years in order to evaluate clinical response and to identify markers that correlate with tumour response to chemotherapy. Assessments required include clinical examinations, mammogram, PET scan, MRI scan, blood tests and biopsy. We believe this study may help us in individualising cancer treatment. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash Medical Centre, Moorabbin Mornington peninsula Hospital</ethicname>
      <ethicaddress>246 Clayton rd, Clayton VIC 3168</ethicaddress>
      <ethicapprovaldate>20/04/2004</ethicapprovaldate>
      <hrec>20/04/20004</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mr</title>
      <name>Peter Midolo</name>
      <address>Medical Oncology
Monash Medical Centre
Southern Health
Moorabbin Centre Road
East Bentleigh VIC 3165</address>
      <phone>+61 3 99288195</phone>
      <fax>+61 3 99288341</fax>
      <email>peter.midolo@monashhealth.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Vinod Ganju</name>
      <address>Medical Oncology
Monash Medical Centre
Southern Health
Moorabbin Centre Road
East Bentleigh VIC 3165</address>
      <phone>+61 3 99288120</phone>
      <fax>+61 3 99288341</fax>
      <email>vg@paso.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr Peter Midolo</name>
      <address>Medical Oncology Monash Medical Centre Southern Health Moorabbin Centre Road East Bentleigh VIC 3165</address>
      <phone>61 3 99288195</phone>
      <fax>61 3 99288195</fax>
      <email>peter.midolo@monashhealth.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Vinod Ganju</name>
      <address>Monash Cancer Centre
865 Centre rd East Bentleigh VIC 3165</address>
      <phone>610399288120</phone>
      <fax />
      <email>vg@paso.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>